High frequency of advanced hepatic disease among HIV/HCV Co-infected patients in Cambodia: The HEPACAM study (ANRS 12267)

Journal of AIDS and Clinical Research

Volumn 3, Issue 6, 2012, Pages

  Lerolle, Nathalie ^a,e   Limsreng, Setha ^b,c   Fournier Nicolle, Isabelle ^d,e   Ly, Sowath ^e   Nouhin, Janin ^e   Guillard, Bertr ^e   Ken, Sreymom ^e   Dulioust, Anne ^a,b   Khuon, Pichit ^b,c   Delfraissy, Jean François ^a,b,d   Ouk, Vara ^b,c   Segeral, Olivier ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b Ensemble pour une Solidarité Thérapeutique Hospitaliere En Réseau' ^*  (France)

^c Calmette Hospital   (Cambodia)

^d Agence Nationale de Recherches Sur le Sida et Les Hépatites Virales ANRS   (France)

^e INSTITUT PASTEUR DU CAMBODGE   (Cambodia)

Author keywords

Cirrhosis; Fibrotest; HCV co infection; HIV; Nevirapine; Resourcelimited country

Indexed keywords

EID: 84879819517     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000161     Document Type: Article

References (47)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
2. Egger M, May M, Chene G, Phillips AN, Ledergerber B, et al. (2002) Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360: 119-129.
3. Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, et al. (2002) Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS 16: 1663-1671.
4. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, et al. (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166: 1632-1641.
5. Lewden C, May T, Rosenthal E, Burty C, Bonnet F, et al. (2008) Changes in causes of death among adults infected by HIV between 2000 and 2005: The "Mortalite 2000 and 2005" surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 48: 590-598.
6. Thein HH, Yi Q, Dore GJ, Krahn MD (2008) Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 22: 1979-1991.
7. Pineda JA, Romero-Gomez M, Diaz-Garcia F, Giron-Gonzalez JA, Montero JL, et al. (2005) HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41: 779-789.
8. Wit FW, Weverling GJ, Weel J, Jurriaans S, Lange JM (2002) Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 186: 23-31.
9. Nunez M (2006) Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 44: S132-S139.
10. Law WP, Dore GJ, Duncombe CJ, Mahanontharit A, Boyd MA, et al. (2003) Risk of severe hepatotoxicity associated with antiretroviral therapy in the HIV-NAT Cohort, Thailand, 1996-2001. AIDS 17: 2191-2199.
11. Soriano V, Puoti M, Sulkowski M, Mauss S, Cacoub P, et al. (2004) Care of patients with hepatitis C and HIV co-infection. AIDS 18: 1-12.
12. Laurent C, Kouanfack C, Koulla-Shiro S, Nkoue N, Bourgeois A, et al. (2004) Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet 364: 29-34.
13. Ivers LC, Kendrick D, Doucette K (2005) Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 41: 217-224.
14. Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, et al. (2007) Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 21: 351-359.
15. Janssens B, Raleigh B, Soeung S, Akao K, Te V, et al. (2007) Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia. Pediatrics 120: e1134-1140.
16. Isaakidis P, Raguenaud ME, Te V, Tray CS, Akao K, et al. (2011) High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia. J Int AIDS Soc 13: 11.
17. Ferradini L, Laureillard D, Prak N, Ngeth C, Fernandez M, et al. (2007) Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia. AIDS 21: 2293-2301.
18. Segeral O, Limsreng S, Nouhin J, Hak C, Ngin S, et al. (2011) Short communication: Three Years Follow-Up of First-Line Antiretroviral Therapy in Cambodia: Negative Impact of Prior Antiretroviral Treatment. AIDS Res Hum Retroviruses 27: 597-603.
19. Thuring EG, Joller-Jemelka HI, Sareth H, Sokhan U, Reth C, et al. (1993) Prevalence of markers of hepatitis viruses A, B, C and of HIV in healthy individuals and patients of a Cambodian province. Southeast Asian J Trop Med Public Health 24: 239-249.
20. Sarmati L, Andreoni M, Suligoi B, Bugarini R, Uccella I, et al. (2003) Infection with human herpesvirus-8 and its correlation with hepatitis B virus and hepatitis C virus markers among rural populations in Cambodia. Am J Trop Med Hyg 68: 501-502.
21. Caruana SR, Kelly HA, De Silva SL, Chea L, Nuon S, et al. (2005) Knowledge about hepatitis and previous exposure to hepatitis viruses in immigrants and refugees from the Mekong Region. Aust N Z J Public Health 29: 64-68.
22. Luksamijarulkul P, Kaepan W, Klamphakorn S (2007) Hepatitis B virus sero-markers, hepatitis C virus antibody and risk behaviors among middle age and older Thai males. Southeast Asian J Trop Med Public Health 38: 45-52.
23. Jutavijittum P, Yousukh A, Samountry B, Samountry K, Ounavong A, et al. (2007) Seroprevalence of hepatitis B and C virus infections among Lao blood donors. Southeast Asian J Trop Med Public Health 38: 674-679.
24. Vong S, Perz JF, Sok S, Som S, Goldstein S, et al. (2005) Rapid assessment of injection practices in Cambodia, 2002. BMC Public Health 5: 56.
25. Dewost AV, Michaud P, Arfaoui S, Gache P, Lancrenon S (2006) Fast alcohol consumption evaluation: a screening instrument adapted for French general practitioners. Alcohol Clin Exp Res 30: 1889-1895.
26. Felsenstein J (1996) Inferring phylogenies from protein sequences by parsimony, distance, and likelihood methods. Methods Enzymol 266: 418-427.
27. Budkowska A, Kakkanas A, Nerrienet E, Kalinina O, Maillard P, et al. (2011) Synonymous mutations in the core gene are linked to unusual serological profile in hepatitis C virus infection. PLoS One 6: e15871.
28. Kesli R, Ozdemir M, Kurtoglu MG, Baykan M, Baysal B (2009) Evaluation and comparison of three different anti-hepatitis C virus antibody tests based on chemiluminescence and enzyme-linked immunosorbent assay methods used in the diagnosis of hepatitis C infections in Turkey. J Int Med Res 37: 1420-1429.
29. Pham DA, Leuangwutiwong P, Jittmittraphap A, Luplertlop N, Bach HK, et al. (2009) High prevalence of Hepatitis C virus genotype 6 in Vietnam. Asian Pac J Allergy Immunol 27: 153-160.
30. Verachai V, Phutiprawan T, Theamboonlers A, Chinchai T, Tanprasert S, et al. (2002) Prevalence and genotypes of hepatitis C virus infection among drug addicts and blood donors in Thailand. Southeast Asian J Trop Med Public Health 33: 849-851.
31. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, et al. (2004) Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292: 2839-2848.
32. Vergara S, Macias J, Rivero A, Gutierrez-Valencia A, Gonzalez-Serrano M, et al. (2007) The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 45: 969-974.
33. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, et al. (2003) Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 17: 721-725.
34. Moreno S, Garcia-Samaniego J, Moreno A, Ortega E, Pineda JA, et al. (2009) Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV co-infection. J Viral Hepat 16: 249-258.
35. Nunes D, Fleming C, Offner G, O'Brien M, Tumilty S, et al. (2005) HIV infection does not affect the performance of noninvasive markers of fibrosis for the diagnosis of hepatitis C virus-related liver disease. J Acquir Immune Defic Syndr 40: 538-544.
36. Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB, et al. (2010) Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 24: 1857-1865.
37. Braitstein P, Zala C, Yip B, Brinkhof MW, Moore D, et al. (2006) Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program. J Infect Dis 193: 259-268.
38. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, et al. (2005) Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 192: 992-1002.
39. Sulkowski MS, Thomas DL, Mehta SH, Chaisson RE, Moore RD (2002) Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 35: 182-189.
40. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, et al. (2000) Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14: 2895-2902.
41. Nunez M, Lana R, Mendoza JL, Martin-Carbonero L, Soriano V (2001) Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 27: 426-431.
42. Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, et al. (2010) Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon. BMC Public Health 10: 105.
43. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, et al. (2003) Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362: 1708-1713.
44. Labarga P, Soriano V, Vispo ME, Pinilla J, Martin-Carbonero L, et al. (2007) Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 196: 670-676.
45. Yu ML, Chuang WL (2009) Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 24: 336-345.
46. Tsang OT, Zee JS, Chan JM, Li RS, Kan YM, et al. (2010) Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1. J Gastroenterol Hepatol 25: 766-771.
47. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.